Long non‑coding RNAs as potential therapeutic targets in non‑small cell lung cancer (Review)

Tang,Peiyu; Sun,Dejuan; Xu,Wei; Li,Hua; Chen,Lixia

doi:10.3892/ijmm.2023.5271

Long non‑coding RNAs as potential therapeutic targets in non‑small cell lung cancer (Review)

Authors:
- Peiyu Tang
- Dejuan Sun
- Wei Xu
- Hua Li
- Lixia Chen
View Affiliations

Affiliations: Wuya College of Innovation, Key Laboratory of Structure‑Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China, Institute of Structural Pharmacology and TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China
Published online on: June 20, 2023 https://doi.org/10.3892/ijmm.2023.5271
Article Number: 68
Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small cell lung cancer (NSCLC) is one of the most common malignancies with a high morbidity and mortality rate. Long non‑coding RNAs (lncRNAs) have been reported to be closely associated with the occurrence and progression of NSCLC. In addition, lncRNAs have been documented to participate in the development of drug resistance and radiation sensitivity in patients with NSCLC. Due to their extensive functional characterization, high tissue specificity and sex specificity, lncRNAs have been proposed to be novel biomarkers and therapeutic targets for NSCLC. Therefore, in the current review, the functional classification of lncRNAs were presented, whilst the potential roles of lncRNAs in NSCLC were also summarized. Various physiological aspects, including proliferation, invasion and drug resistance, were all discussed. It is anticipated that the present review will provide a perspective on lncRNAs as potential diagnostic molecular biomarkers and therapeutic targets for NSCLC.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar
2	Xie S, Wu Z, Qi Y, Wu B and Zhu X: The metastasizing mechanisms of lung cancer: Recent advances and therapeutic challenges. Biomed Pharmacother. 138:1114502021. View Article : Google Scholar
3	Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, et al: Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 48:607–616. 2016. View Article : Google Scholar : PubMed/NCBI
4	Chaft JE, Rimner A, Weder W, Azzoli CG, Kris MG and Cascone T: Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol. 18:547–557. 2021. View Article : Google Scholar : PubMed/NCBI
5	Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, Mariotto AB, Lowy DR and Feuer EJ: The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 383:640–649. 2020. View Article : Google Scholar
6	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI
7	Sheng GT, Duan HJ, Sun ZG and Chu HQ: Advances in therapeutic nanodrug delivery systems for infectious lung diseases: A review. Acta Materia Medica. 1:343–364. 2022. View Article : Google Scholar
8	Ginn L, Shi L, Montagna M and Garofalo M: LncRNAs in non-small-cell lung cancer. Noncoding RNA. 6:252020.PubMed/NCBI
9	Li Z, Meng X, Wu P, Zha C, Han B, Li L, Sun N, Qi T, Qin J, Zhang Y, et al: Glioblastoma Cell-Derived lncRNA-containing exosomes induce microglia to produce complement C5, promoting chemotherapy resistance. Cancer Immunol Res. 9:1383–1399. 2021. View Article : Google Scholar
10	Rinn JL and Chang HY: Genome regulation by long noncoding RNAs. Annu Rev Biochem. 81:145–166. 2012. View Article : Google Scholar
11	Bánfai B, Jia H, Khatun J, Wood E, Risk B, Gundling WE Jr, Kundaje A, Gunawardena HP, Yu Y, Xie L, et al: Long noncoding RNAs are rarely translated in two human cell lines. Genome Res. 22:1646–1657. 2012. View Article : Google Scholar :
12	Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, et al: Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 458:223–227. 2009. View Article : Google Scholar :
13	Wang S, Zeng F, Liang S, Wang Q, Wen Y, Wang Q, Zhang J, Li M, Fang S, Wei T, et al: lncRNA Linc00173 modulates glucose metabolism and multidrug chemoresistance in SCLC: Potential molecular panel for targeted therapy. Mol Ther. 30:17872022. View Article : Google Scholar :
14	Qiao Y, Jin T, Guan S, Cheng S, Wen S, Zeng H, Zhao M, Yang L, Wan X, Qiu Y, et al: Long non-coding RNA Lnc-408 promotes invasion and metastasis of breast cancer cell by regulating LIMK1. Oncogene. 40:4198–4213. 2021. View Article : Google Scholar : PubMed/NCBI
15	Du M, Zheng R, Ma G, Chu H, Lu J, Li S, Xin J, Tong N, Zhang G, Wang W, et al: Remote modulation of lncRNA GCLET by risk variant at 16p13 underlying genetic susceptibility to gastric cancer. Sci Adv. 6:eaay55252020. View Article : Google Scholar : PubMed/NCBI
16	Zhao W and Xie Q: Exosomal lncRNA-Mediated intercellular communication promotes glioblastoma chemoresistance. Cancer Immunol Res. 9:13722021. View Article : Google Scholar : PubMed/NCBI
17	Zhang B, Zhang M, Yang Y, Li Q, Yu J, Zhu S, Niu Y and Shang Z: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC. Oncogene. 41:387–399. 2022. View Article : Google Scholar :
18	Meessen J, Bär C, di Dona FM, Staszewsky LI, Di Giulio P, Di Tano G, Costa A, Leonardy J, Novelli D, Nicolis EB, et al: LIPCAR Is increased in chronic symptomatic HF patients. A Sub-Study of the GISSI-HF trial. Clin Chem. 67:1721–1731. 2021. View Article : Google Scholar : PubMed/NCBI
19	Zheng X, Zhang J, Fang T, Wang X, Wang S, Ma Z, Xu Y, Han C, Sun M, Xu L, et al: The long non-coding RNA PIK3CD-AS2 promotes lung adenocarcinoma progression via YBX1-mediated suppression of p53 pathway. Oncogenesis. 9:342020. View Article : Google Scholar : PubMed/NCBI
20	Eidem TM, Kugel JF and Goodrich JA: Noncoding RNAs: Regulators of the mammalian transcription machinery. J Mol Biol. 428:2652–2659. 2016. View Article : Google Scholar : PubMed/NCBI
21	Tao H, Zhang Y, Li J, Liu J, Yuan T, Wang W, Liang H, Zhang E and Huang Z: Oncogenic lncRNA BBOX1-AS1 promotes PHF8-mediated autophagy and elicits sorafenib resistance in hepatocellular carcinoma. Mol Ther Oncolytics. 28:88–103. 2023. View Article : Google Scholar :
22	Liu B, Qu X, Wang J, Xu L, Zhang L, Xu B, Su J and Bian X: LINC00365 functions as a tumor suppressor by inhibiting HIF-1α-mediated glucose metabolism reprogramming in breast cancer. Exp Cell Res. 425:1135142023. View Article : Google Scholar
23	Kopp F and Mendell JT: Functional classification and experimental dissection of long noncoding RNAs. Cell. 172:393–407. 2018. View Article : Google Scholar :
24	Brownmiller T, Juric JA, Ivey AD, Harvey BM, Westemeier ES, Winters MT, Stevens AM, Stanley AN, Hayes KE, Sprowls SA, et al: Y Chromosome LncRNA are involved in radiation response of male non-small cell lung cancer cells. Cancer Res. 80:4046–4057. 2020. View Article : Google Scholar : PubMed/NCBI
25	Sun Q, Hao Q and Prasanth KV: Nuclear long noncoding RNAs: Key regulators of gene expression. Trends Genet. 34:142–157. 2018. View Article : Google Scholar :
26	Noh JH, Kim KM, McClusky WG, Abdelmohsen K and Gorospe M: Cytoplasmic functions of long noncoding RNAs. Wiley Interdiscip Rev RNA. 9:e14712018. View Article : Google Scholar : PubMed/NCBI
27	Jing X, Yang F, Shao C, Wei K, Xie M, Shen H and Shu Y: Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 18:1572019. View Article : Google Scholar : PubMed/NCBI
28	Kashihara M, Azuma K, Kawahara A, Basaki Y, Hattori S, Yanagawa T, Terazaki Y, Takamori S, Shirouzu K, Aizawa H, et al: Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer. J Thorac Oncol. 4:1066–1074. 2009. View Article : Google Scholar : PubMed/NCBI
29	Cui Y, Li F, Xie Q, Zhao S, Guo T, Guo P, Hu S, Hao J, Tian C, Yu W, et al: YBX1 mediates autophagy by targeting p110β and decreasing the sensitivity to cisplatin in NSCLC. Cell Death Dis. 11:4762020. View Article : Google Scholar
30	Zhao Y, Zhou L, Li H, Sun T, Wen X, Li X, Meng Y, Li Y, Liu M, Liu S, et al: Nuclear-Encoded lncRNA MALAT1 epigenetically controls metabolic reprogramming in HCC cells through the mitophagy pathway. Mol Ther Nucleic Acids. 23:264–276. 2021. View Article : Google Scholar
31	Cao DW, Liu MM, Duan R, Tao YF, Zhou JS, Fang WR, Zhu JR, Niu L and Sun JG: The lncRNA Malat1 functions as a ceRNA to contribute to berberine-mediated inhibition of HMGB1 by sponging miR-181c-5p in poststroke inflammation. Acta Pharmacol Sin. 41:22–33. 2020. View Article : Google Scholar
32	Barik GK, Sahay O, Behera A, Naik D and Kalita B: Keep your eyes peeled for long noncoding RNAs: Explaining their boundless role in cancer metastasis, drug resistance, and clinical application. Biochim Biophys Acta Rev Cancer. 1876:1886122021. View Article : Google Scholar : PubMed/NCBI
33	Knutsen E, Harris AL and Perander M: Expression and functions of long non-coding RNA NEAT1 and isoforms in breast cancer. Br J Cancer. 126:551–561. 2022. View Article : Google Scholar
34	Wang D, Zhang S, Zhao M and Chen F: LncRNA MALAT1 accelerates non-small cell lung cancer progression via regulating miR-185-5p/MDM4 axis. Cancer Med. 9:9138–9149. 2020. View Article : Google Scholar : PubMed/NCBI
35	Li M, Shi M, Hu C, Chen B and Li S: MALAT1 modulated FOXP3 ubiquitination then affected GINS1 transcription and drived NSCLC proliferation. Oncogene. 40:3870–3884. 2021. View Article : Google Scholar : PubMed/NCBI
36	Yang L, Chen Y, Cui T, Knösel T, Zhang Q, Albring KF, Huber O and Petersen I: Desmoplakin acts as a tumor suppressor by inhibition of the Wnt/β-catenin signaling pathway in human lung cancer. Carcinogenesis. 33:1863–1870. 2012. View Article : Google Scholar : PubMed/NCBI
37	Wang R, Liu J, Li K, Yang G, Chen S, Wu J, Xie X, Ren H and Pang Y: An SETD1A/Wnt/β-catenin feedback loop promotes NSCLC development. J Exp Clin Cancer Res. 40:3182021. View Article : Google Scholar
38	Liao Y, Feng J, Sun W, Wu C, Li J, Jing T, Liang Y, Qian Y, Liu W, Wang H, et al: CIRP promotes the progression of non-small cell lung cancer through activation of Wnt/β-catenin signaling via CTNNB1. J Exp Clin Cancer Res. 40:2752021. View Article : Google Scholar
39	Shapiro M, Akiri G, Chin C, Wisnivesky JP, Beasley MB, Weiser TS, Swanson SJ and Aaronson SA: Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancer. Ann Surg. 257:548–554. 2013. View Article : Google Scholar
40	Pang B, Wang Y and Chang X: A Novel Tumor suppressor gene, ZNF24, inhibits the development of NSCLC by inhibiting the WNT signaling pathway to induce cell senescence. Front Oncol. 11:6643692021. View Article : Google Scholar : PubMed/NCBI
41	Zhang K, Wang J, Yang L, Yuan YC, Tong TR, Wu J, Yun X, Bonner M, Pangeni R, Liu Z, et al: Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1α and APC2 gene expression in non-small cell lung cancer. Mol Cancer. 17:1532018. View Article : Google Scholar
42	Han X, Jiang H, Qi J, Li J, Yang J, Tian Y, Li W, Jing Q and Wang C: Novel lncRNA UPLA1 mediates tumorigenesis and prognosis in lung adenocarcinoma. Cell Death Dis. 11:9992020. View Article : Google Scholar : PubMed/NCBI
43	Wang J, Cai H, Dai Z and Wang G: Down-regulation of lncRNA XIST inhibits cell proliferation via regulating miR-744/RING1 axis in non-small cell lung cancer. Clin Sci (Lond). 133:1567–1579. 2019. View Article : Google Scholar : PubMed/NCBI
44	Kun E, Tsang YTM, Ng CW, Gershenson DM and Wong KK: MEK inhibitor resistance mechanisms and recent developments in combination trials. Cancer Treat Rev. 92:1021372021. View Article : Google Scholar
45	Weissman R, Diamond EL, Haroche J, Durham BH, Cohen F, Buthorn J, Amoura Z, Emile JF, Mazor RD, Shomron N, et al: MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis. Leukemia. 36:1139–1149. 2022. View Article : Google Scholar :
46	Han J, Liu Y, Yang S, Wu X, Li H and Wang Q: MEK inhibitors for the treatment of non-small cell lung cancer. J Hematol Oncol. 14:12021. View Article : Google Scholar : PubMed/NCBI
47	Liu HY, Lu SR, Guo ZH, Zhang ZS, Ye X, Du Q, Li H, Wu Q, Yu B, Zhai Q, et al: lncRNA SLC16A1-AS1 as a novel prognostic biomarker in non-small cell lung cancer. J Investig Med. 68:52–59. 2020. View Article : Google Scholar :
48	Logotheti S, Marquardt S, Gupta SK, Richter C, Edelhäuser BAH, Engelmann D, Brenmoehl J, Söhnchen C, Murr N, Alpers M, et al: LncRNA-SLC16A1-AS1 induces metabolic reprogramming during bladder cancer progression as target and co-activator of E2F1. Theranostics. 10:9620–9643. 2020. View Article : Google Scholar : PubMed/NCBI
49	Zang X, Gu J, Zhang J, Shi H, Hou S, Xu X, Chen Y, Zhang Y, Mao F, Qian H, et al: Exosome-transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression. Cell Death Dis. 11:2152020. View Article : Google Scholar : PubMed/NCBI
50	Yang Z, Lin X, Zhang P, Liu Y, Liu Z, Qian B, Liu X and Shao G: Long non-coding RNA LINC00525 promotes the non-small cell lung cancer progression by targeting miR-338-3p/IRS2 axis. Biomed Pharmacother. 124:1098582020. View Article : Google Scholar : PubMed/NCBI
51	Fang P, Chen H, Ma Z, Han C, Yin W, Wang S, Zhu H, Xia W, Wang J, Xu L, et al: LncRNA LINC00525 suppresses p21 expression via mRNA decay and triplex-mediated changes in chromatin structure in lung adenocarcinoma. Cancer Commun (Lond). 41:596–614. 2021. View Article : Google Scholar : PubMed/NCBI
52	Yang M, He X, Huang X, Wang J, He Y and Wei L: LncRNA MIR4435-2HG-mediated upregulation of TGF-β1 promotes migration and proliferation of nonsmall cell lung cancer cells. Environ Toxicol. 35:582–590. 2020. View Article : Google Scholar
53	Xu F, Hua Q, Zhang A, Di Z, Wang Y, Zhao L, Yang H, Liu J and Huang G: LncRNA AC020978 facilitates non-small cell lung cancer progression by interacting with malate dehydrogenase 2 and activating the AKT pathway. Cancer Sci. 112:4501–4514. 2021. View Article : Google Scholar : PubMed/NCBI
54	Cai Y, Wu Q, Liu Y and Wang J: AZIN1-AS1, A novel oncogenic LncRNA, promotes the progression of non-small cell lung cancer by regulating MiR-513b-5p and DUSP11. Onco Targets Ther. 13:9667–9678. 2020. View Article : Google Scholar : PubMed/NCBI
55	Wu S, Liu B, Zhang Y, Hong R, Liu S, Xiang T, Tao T, Cai J, Wu J, Li M and Guan H: Long non-coding RNA LEISA promotes progression of lung adenocarcinoma via enhancing interaction between STAT3 and IL-6 promoter. Oncogene. 40:3449–3459. 2021. View Article : Google Scholar : PubMed/NCBI
56	Wang RQ, Long XR, Zhou NN, Chen DN, Zhang MY, Wen ZS, Zhang LJ, He FZ, Zhou ZL, Mai SJ and Wang HY: Lnc-GAN1 expression is associated with good survival and suppresses tumor progression by sponging mir-26a-5p to activate PTEN signaling in non-small cell lung cancer. J Exp Clin Cancer Res. 40:92021. View Article : Google Scholar : PubMed/NCBI
57	Li C, Zhao W, Pan X, Li X, Yan F, Liu S, Feng J and Lu J: LncRNA KTN1-AS1 promotes the progression of non-small cell lung cancer via sponging of miR-130a-5p and activation of PDPK1. Oncogene. 39:6157–6171. 2020. View Article : Google Scholar : PubMed/NCBI
58	Liu C, Li X, Hao Y, Wang F, Cheng Z, Geng H and Geng D: STAT1-induced upregulation of lncRNA KTN1-AS1 predicts poor prognosis and facilitates non-small cell lung cancer progression via miR-23b/DEPDC1 axis. Aging (Albany NY). 12:8680–8701. 2020. View Article : Google Scholar : PubMed/NCBI
59	Zhu Y, Li J, Bo H, He D, Xiao M, Xiang L, Gong L, Hu Y, Zhang Y, Cheng Y, et al: LINC00467 is up-regulated by TDG-mediated acetylation in non-small cell lung cancer and promotes tumor progression. Oncogene. 39:6071–6084. 2020. View Article : Google Scholar : PubMed/NCBI
60	Yang J, Liu Y, Mai X, Lu S, Jin L and Tai X: STAT1-induced upregulation of LINC00467 promotes the proliferation migration of lung adenocarcinoma cells by epigenetically silencing DKK1 to activate Wnt/β-catenin signaling pathway. Biochem Biophys Res Commun. 514:118–126. 2019. View Article : Google Scholar : PubMed/NCBI
61	Chang Y and Yang L: LINC00467 promotes cell proliferation and stemness in lung adenocarcinoma by sponging miR-4779 and miR-7978. J Cell Biochem. 121:3691–3699. 2019. View Article : Google Scholar : PubMed/NCBI
62	Xue F, Yang C, Yun K, Jiang C, Cai R, Liang M, Wang Q, Bian W, Zhou H, Liu Z and Zhu L: RETRACTED ARTICLE: Reduced LINC00467 elevates microRNA-125a-3p to suppress cisplatin resistance in non-small cell lung cancer through inhibiting sirtuin 6 and inactivating the ERK1/2 signaling pathway. Cell Biol Toxicol. 39:3652023. View Article : Google Scholar
63	Yin H, Chen L, Piao S, Wang Y, Li Z, Lin Y, Tang X, Zhang H, Zhang H and Wang X: M6A RNA methylation-mediated RMRP stability renders proliferation and progression of non-small cell lung cancer through regulating TGFBR1/SMAD2/SMAD3 pathway. Cell Death Differ. 30:605–617. 2023. View Article : Google Scholar
64	Sun CC, Zhu W, Li SJ, Hu W, Zhang J, Zhuo Y, Zhang H, Wang J, Zhang Y, Huang SX, et al: Correction to: FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway. Genome Med. 13:252021. View Article : Google Scholar
65	Shi L, Magee P, Fassan M, Sahoo S, Leong HS, Lee D, Sellers R, Brullé-Soumaré L, Cairo S, Monteverde T, et al: A KRAS-responsive long non-coding RNA controls microRNA processing. Nat Commun. 12:20382021. View Article : Google Scholar : PubMed/NCBI
66	La Montagna M, Shi L, Magee P, Sahoo S, Fassan M and Garofalo M: AMPKα loss promotes KRAS-mediated lung tumorigenesis. Cell Death Differ. 28:2673–2689. 2021. View Article : Google Scholar : PubMed/NCBI
67	Shi J, Yang C, An J, Hao D, Liu C, Liu J, Sun J and Jiang J: KLF5-induced BBOX1-AS1 contributes to cell malignant phenotypes in non-small cell lung cancer via sponging miR-27a-5p to up-regulate MELK and activate FAK signaling pathway. J Exp Clin Cancer Res. 40:1482021. View Article : Google Scholar : PubMed/NCBI
68	Ni J, Zhang X, Li J, Zheng Z, Zhang J, Zhao W and Liu L: Tumour-derived exosomal lncRNA-SOX2OT promotes bone metastasis of non-small cell lung cancer by targeting the miRNA-194-5p/RAC1 signalling axis in osteoclasts. Cell Death Dis. 12:6622021. View Article : Google Scholar : PubMed/NCBI
69	Lv X, Lian Y, Liu Z, Xiao J, Zhang D and Yin X: Exosomal long non-coding RNA LINC00662 promotes non-small cell lung cancer progression by miR-320d/E2F1 axis. Aging (Albany NY). 13:6010–6024. 2021. View Article : Google Scholar : PubMed/NCBI
70	Liu S, Zhan N, Gao C, Xu P, Wang H, Wang S, Piao S and Jing S: Long noncoding RNA CBR3-AS1 mediates tumorigenesis and radiosensitivity of non-small cell lung cancer through redox and DNA repair by CBR3-AS1/miR-409-3p/SOD1 axis. Cancer Lett. 526:1–11. 2022. View Article : Google Scholar
71	Wang C, Meng X, Zhou Y, Yu J, Li Q, Liao Z, Gu Y, Han J, Linghu S, Jiao Z, et al: Long Noncoding RNA CTD-2245E15.3 Promotes Anabolic Enzymes ACC1 and PC to support non-small cell lung cancer growth. Cancer Res. 81:3509–3524. 2021. View Article : Google Scholar : PubMed/NCBI
72	Wang S, Wang T, Liu D and Kong H: LncRNA MALAT1 aggravates the progression of non-small cell lung cancer by stimulating the expression of COMMD8 via targeting miR-613. Cancer Manag Res. 12:10735–10747. 2020. View Article : Google Scholar : PubMed/NCBI
73	Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, Di W, Hu B, An J, Kong L, et al: m⁶A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. J Hematol Oncol. 12:1352019. View Article : Google Scholar
74	Jin S, He J, Zhou Y, Wu D, Li J and Gao W: LncRNA FTX activates FOXA2 expression to inhibit non-small-cell lung cancer proliferation and metastasis. J Cell Mol Med. 24:4839–4849. 2020. View Article : Google Scholar : PubMed/NCBI
75	Sun J, Xiong Y, Jiang K, Xin B, Jiang T, Wei R, Zou Y, Tan H, Jiang T, Yang A, et al: Hypoxia-sensitive long noncoding RNA CASC15 promotes lung tumorigenesis by regulating the SOX4/β-catenin axis. J Exp Clin Cancer Res. 40:122021. View Article : Google Scholar
76	Fan H, Yuan J, Li Y, Jia Y, Li J, Wang X and Li X: MKL1-induced lncRNA SNHG18 drives the growth and metastasis of non-small cell lung cancer via the miR-211-5p/BRD4 axis. Cell Death Dis. 12:1282021. View Article : Google Scholar : PubMed/NCBI
77	Chen J, Liu A, Wang Z, Wang B, Chai X, Lu W, Cao T, Li R, Wu M, Lu Z, et al: LINC00173.v1 promotes angiogenesis and progression of lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression. Mol Cancer. 19:982020. View Article : Google Scholar : PubMed/NCBI
78	Xiao L, Li Y, Zeng X, Zhou Z, Hu S, Zhang S, Zhou Y, Zhang Z, Zhao H, Zhao H, et al: Silencing of LOC389641 impairs cell proliferation and induces autophagy via EGFR/MET signaling in lung adenocarcinoma. Aging (Albany NY). 13:2539–2552. 2020. View Article : Google Scholar : PubMed/NCBI
79	Cao G, Tan B, Wei S, Shen W, Wang X, Chu Y, Rong T and Gao C: Down-regulation of MBNL1-AS1 contributes to tumorigenesis of NSCLC via sponging miR-135a-5p. Biomed Pharmacother. 125:1098562020. View Article : Google Scholar : PubMed/NCBI
80	Hua Q, Mi B, Xu F, Wen J, Zhao L, Liu J and Huang G: Hypoxia-induced lncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1α axis. Theranostics. 10:4762–4778. 2020. View Article : Google Scholar :
81	Chen Q, Guo SM, Huang HQ, Huang GP, Li Y, Li ZH, Huang R, Xiao L, Fan CR, Yuan Q and Zheng SL: Long noncoding RNA SBF2-AS1 contributes to the growth and metastatic phenotypes of NSCLC via regulating miR-338-3p/ADAM17 axis. Aging (Albany NY). 12:17902–17920. 2020. View Article : Google Scholar : PubMed/NCBI
82	Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6. 1990. View Article : Google Scholar : PubMed/NCBI
83	Quinodoz SA, Jachowicz JW, Bhat P, Ollikainen N, Banerjee AK, Goronzy IN, Blanco MR, Chovanec P, Chow A, Markaki Y, et al: RNA promotes the formation of spatial compartments in the nucleus. Cell. 184:5775–5790.e5730. 2021. View Article : Google Scholar : PubMed/NCBI
84	Markaki Y, Gan Chong J, Wang Y, Jacobson EC, Luong C, Tan SYX, Jachowicz JW, Strehle M, Maestrini D, Banerjee AK, et al: Xist nucleates local protein gradients to propagate silencing across the X chromosome. Cell. 184:6174–6192.e6132. 2021. View Article : Google Scholar : PubMed/NCBI
85	Guo Z, Dai Y, Hu W, Zhang Y, Cao Z, Pei W, Liu N, Nie J, Wu A, Mao W, et al: The long noncoding RNA CRYBG3 induces aneuploidy by interfering with spindle assembly checkpoint via direct binding with Bub3. Oncogene. 40:1821–1835. 2021. View Article : Google Scholar : PubMed/NCBI
86	Tian B, Han X, Li G, Jiang H, Qi J, Li J, Tian Y and Wang C: A Long intergenic non-coding RNA, LINC01426, promotes cancer progression via AZGP1 and predicts poor prognosis in patients with LUAD. Mol Ther Methods Clin Dev. 18:765–780. 2020. View Article : Google Scholar : PubMed/NCBI
87	Liu X, Yin Z, Xu L, Liu H, Jiang L, Liu S and Sun X: Upregulation of LINC01426 promotes the progression and stemness in lung adenocarcinoma by enhancing the level of SHH protein to activate the hedgehog pathway. Cell Death Dis. 12:1732021. View Article : Google Scholar : PubMed/NCBI
88	Jia D, Xing Y, Zhan Y, Cao M, Tian F, Fan W, Huang J, Cui Y, Gu R, Cui Y, et al: LINC02678 as a novel prognostic marker promotes aggressive non-small-cell lung cancer. Front Cell Dev Biol. 9:6869752021. View Article : Google Scholar : PubMed/NCBI
89	Chen Z, Chen X, Lei T, Gu Y, Gu J, Huang J, Lu B, Yuan L, Sun M and Wang Z: Integrative analysis of NSCLC identifies LINC01234 as an oncogenic lncRNA that interacts with HNRNPA2B1 and regulates miR-106b biogenesis. Mol Ther. 28:1479–1493. 2020. View Article : Google Scholar : PubMed/NCBI
90	Chen Z, Chen X, Lu B, Gu Y, Chen Q, Lei T, Nie F, Gu J, Huang J, Wei C, et al: Up-regulated LINC01234 promotes non-small-cell lung cancer cell metastasis by activating VAV3 and repressing BTG2 expression. J Hematol Oncol. 13:72020. View Article : Google Scholar : PubMed/NCBI
91	Zheng F, Li J, Ma C, Tang X, Tang Q, Wu J, Chai X, Xie J, Yang XB and Hann SS: Novel regulation of miR-34a-5p and HOTAIR by the combination of berberine and gefitinib leading to inhibition of EMT in human lung cancer. J Cell Mol Med. 24:5578–5592. 2020. View Article : Google Scholar : PubMed/NCBI
92	Hua Q, Jin M, Mi B, Xu F, Li T, Zhao L, Liu J and Huang G: LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis. J Hematol Oncol. 12:912019. View Article : Google Scholar : PubMed/NCBI
93	Zhang M, Han Y, Zheng Y, Zhang Y, Zhao X, Gao Z and Liu X: ZEB1-activated LINC01123 accelerates the malignancy in lung adenocarcinoma through NOTCH signaling pathway. Cell Death Dis. 11:9812020. View Article : Google Scholar : PubMed/NCBI
94	Chen H, Liu H and Qing G: Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 3:52018. View Article : Google Scholar : PubMed/NCBI
95	Gabay M, Li Y and Felsher DW: MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med. 4:a0142412014. View Article : Google Scholar : PubMed/NCBI
96	Scafuro M, Capasso L, Carafa V, Altucci L and Nebbioso A: Gene Transactivation and Transrepression in MYC-Driven Cancers. Int J Mol Sci. 22:34582021. View Article : Google Scholar : PubMed/NCBI
97	Vervoort SJ, van Boxtel R and Coffer PJ: The role of SRY-related HMG box transcription factor 4 (SOX4) in tumorigenesis and metastasis: friend or foe? Oncogene. 32:3397–3409. 2013. View Article : Google Scholar
98	Zhang J, Liang Q, Lei Y, Yao M, Li L, Gao X, Feng J, Zhang Y, Gao H, Liu DX, et al: SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression. Cancer Res. 72:4597–4608. 2012. View Article : Google Scholar : PubMed/NCBI
99	Sun CC, Zhu W, Li SJ, Hu W, Zhang J, Zhuo Y, Zhang H, Wang J, Zhang Y, Huang SX, et al: FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway. Genome Med. 12:772020. View Article : Google Scholar
100	Lu Z, Fang Z, Guo Y, Liu X and Chen S: Cisplatin resistance of NSCLC cells involves upregulation of visfatin through activation of its transcription and stabilization of mRNA. Chem Biol Interact. 351:1097052022. View Article : Google Scholar
101	Błach J, Wojas-Krawczyk K, Nicoś M and Krawczyk P: Failure of immunotherapy-the molecular and immunological origin of immunotherapy resistance in lung cancer. Int J Mol Sci. 22:90302021. View Article : Google Scholar
102	Wang CJ, Zhu CC, Xu J, Wang M, Zhao WY, Liu Q, Zhao G and Zhang ZZ: The lncRNA UCA1 promotes proliferation, migration, immune escape and inhibits apoptosis in gastric cancer by sponging anti-tumor miRNAs. Mol Cancer. 18:1152019. View Article : Google Scholar : PubMed/NCBI
103	Wei MM and Zhou GB: Long Non-coding RNAs and their roles in non-small-cell lung cancer. Genomics Proteomics Bioinformatics. 14:280–288. 2016. View Article : Google Scholar : PubMed/NCBI
104	Huang J, Pan B, Xia G, Zhu J, Li C and Feng J: LncRNA SNHG15 regulates EGFR-TKI acquired resistance in lung adenocarcinoma through sponging miR-451 to upregulate MDR-1. Cell Death Dis. 11:5252020. View Article : Google Scholar : PubMed/NCBI
105	Chen Z, Chen Q, Cheng Z, Gu J, Feng W, Lei T, Huang J, Pu J, Chen X and Wang Z: Long non-coding RNA CASC9 promotes gefitinib resistance in NSCLC by epigenetic repression of DUSP1. Cell Death Dis. 11:8582020. View Article : Google Scholar : PubMed/NCBI
106	Bing Z, Han J, Zheng Z and Liang N: FOXO3-induced oncogenic lncRNA CASC9 enhances gefitinib resistance of non-small-cell lung cancer through feedback loop. Life Sci. 287:1200122021. View Article : Google Scholar : PubMed/NCBI
107	Li Z, Niu H, Qin Q, Yang S, Wang Q, Yu C, Wei Z, Jin Z, Wang X, Yang A and Chen X: lncRNA UCA1 mediates resistance to cisplatin by regulating the miR-143/FOSL2-Signaling pathway in ovarian cancer. Mol Ther Nucleic Acids. 17:92–101. 2019. View Article : Google Scholar : PubMed/NCBI
108	Li C, Fan K, Qu Y, Zhai W, Huang A, Sun X and Xing S: Deregulation of UCA1 expression may be involved in the development of chemoresistance to cisplatin in the treatment of non-small-cell lung cancer via regulating the signaling pathway of microRNA-495/NRF2. J Cell Physiol. 235:3721–3730. 2020. View Article : Google Scholar
109	Xu T, Yan S, Wang M, Jiang L, Ma P, Lu B, Chen Q, Wei C and Wang Z: LncRNA UCA1 induces acquired resistance to gefitinib by epigenetically silencing cdkn1a expression in non-small-cell lung cancer. Front Oncol. 10:6562020. View Article : Google Scholar : PubMed/NCBI
110	Wang H, Lu B, Ren S, Wu F, Wang X, Yan C and Wang Z: Long Noncoding RNA LINC01116 contributes to gefitinib resistance in non-small cell lung cancer through regulating IFI44. Mol Ther Nucleic Acids. 19:218–227. 2020. View Article : Google Scholar
111	Fu J, Cai H, Wu Y, Fang S and Wang D: Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis. Gene. 755:1448862020. View Article : Google Scholar : PubMed/NCBI
112	He H, Song X, Yang Z, Mao Y, Zhang K, Wang Y, Su B, Li Q, Chen H and Li Y: Upregulation of KCNQ1OT1 promotes resistance to stereotactic body radiotherapy in lung adenocarcinoma by inducing ATG5/ATG12-mediated autophagy via miR-372-3p. Cell Death Dis. 11:8832020. View Article : Google Scholar : PubMed/NCBI
113	Dong Z, Yang P, Qiu X, Liang S, Guan B, Yang H, Li F, Sun L, Liu H, Zou G and Zhao K: KCNQ1OT1 facilitates progression of non-small-cell lung carcinoma via modulating miRNA-27b-3p/HSP90AA1 axis. J Cell Physiol. 234:11304–11314. 2019. View Article : Google Scholar
114	Shu D, Xu Y and Chen W: Knockdown of lncRNA BLACAT1 reverses the resistance of afatinib to non-small cell lung cancer via modulating STAT3 signalling. J Drug Target. 28:300–306. 2020. View Article : Google Scholar
115	Ju ZS, Sun B, Bao D and Zhang XF: Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression. Eur Rev Med Pharmacol Sci. 24:9465–9472. 2020.PubMed/NCBI
116	Zeng Z, Zhao G, Zhu H, Nie L, He L, Liu J, Li R, Xiao S and Hua G: LncRNA FOXD3-AS1 promoted chemo-resistance of NSCLC cells via directly acting on miR-127-3p/MDM2 axis. Cancer Cell Int. 20:3502020. View Article : Google Scholar : PubMed/NCBI
117	Yang D, Feng W, Zhuang Y, Liu J, Feng Z, Xu T, Wang W, Zhu Y and Wang Z: Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells. Mol Ther Nucleic Acids. 23:1053–1065. 2021. View Article : Google Scholar : PubMed/NCBI
118	Yu Z, Wang G, Zhang C, Liu Y, Chen W, Wang H and Liu H: LncRNA SBF2-AS1 affects the radiosensitivity of non-small cell lung cancer via modulating microRNA-302a/MBNL3 axis. Cell Cycle. 19:300–316. 2020. View Article : Google Scholar : PubMed/NCBI
119	Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H, et al: Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19. bioRxiv. 2021.
120	Gaston J, Cheradame L, Yvonnet V, Deas O, Poupon MF, Judde JG, Cairo S and Goffin V: Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents. Oncotarget. 7:77205–77224. 2016. View Article : Google Scholar : PubMed/NCBI
121	Duarte CW, Willey CD, Zhi D, Cui X, Harris JJ, Vaughan LK, Mehta T, McCubrey RO, Khodarev NN, Weichselbaum RR and Gillespie GY: Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS One. 7:e296532012. View Article : Google Scholar : PubMed/NCBI
122	Wang J, Gao J, Chen Q, Zou W, Yang F, Wei C and Wang Z: LncRNA LINC01116 contributes to cisplatin resistance in lung adenocarcinoma. Onco Targets Ther. 13:9333–9348. 2020. View Article : Google Scholar : PubMed/NCBI
123	Geng W, Lv Z, Fan J, Xu J, Mao K, Yin Z, Qing W and Jin Y: Identification of the prognostic significance of somatic Mutation-Derived LncRNA signatures of genomic instability in lung adenocarcinoma. Front Cell Dev Biol. 9:6576672021. View Article : Google Scholar : PubMed/NCBI
124	Zeng L, Lyu X, Yuan J, Wang W, Zhao N, Liu B, Sun R, Meng X and Yang S: Long non-coding RNA LINC01116 is overexpressed in lung adenocarcinoma and promotes tumor proliferation and metastasis. Am J Transl Res. 12:4302–4313. 2020.PubMed/NCBI
125	Shang B, Li Z, Li M, Jiang S, Feng Z, Cao Z and Wang H: Silencing LINC01116 suppresses the development of lung adenocarcinoma via the AKT signaling pathway. Thorac Cancer. 12:2093–2103. 2021. View Article : Google Scholar : PubMed/NCBI
126	Yao J, Chen X, Liu X, Li R, Zhou X and Qu Y: Characterization of a ferroptosis and iron-metabolism related lncRNA signature in lung adenocarcinoma. Cancer Cell Int. 21:3402021. View Article : Google Scholar : PubMed/NCBI
127	Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF, Spigel DR, Garassino MC, Reck M, Senan S, et al: Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial. J Thorac Oncol. 16:860–867. 2021. View Article : Google Scholar : PubMed/NCBI
128	Chen Y, Gao M, Huang Z, Yu J and Meng X: SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: A focus on the mechanisms, advances, and future challenges. J Hematol Oncol. 13:1052020. View Article : Google Scholar : PubMed/NCBI
129	Nickoloff JA: Toward greater precision in cancer radiotherapy. Cancer Res. 81:3156–3157. 2021. View Article : Google Scholar : PubMed/NCBI
130	Tu X, Qin B, Zhang Y, Zhang C, Kahila M, Nowsheen S, Yin P, Yuan J, Pei H, Li H, et al: PD-L1 (B7-H1) Competes with the RNA exosome to regulate the DNA damage response and can be targeted to sensitize to radiation or chemotherapy. Mol Cell. 74:1215–1226.e4. 2019. View Article : Google Scholar : PubMed/NCBI
131	Tchelebi LT, Eng C, Messick CA, Hong TS, Ludmir EB, Kachnic LA and Zaorsky NG: Current treatment and future directions in the management of anal cancer. CA Cancer J Clin. 72:183–195. 2022. View Article : Google Scholar
132	Barcena-Varela M and Lujambio A: A novel long noncoding RNA finetunes the DNA damage response in hepatocellular carcinoma. Cancer Res. 81:4899–4900. 2021. View Article : Google Scholar : PubMed/NCBI
133	Liu JY, Chen YJ, Feng HH, Chen ZL, Wang YL, Yang JE and Zhuang SM: LncRNA SNHG17 interacts with LRPPRC to stabilize c-Myc protein and promote G1/S transition and cell proliferation. Cell Death Dis. 12:9702021. View Article : Google Scholar : PubMed/NCBI
134	Wang Y, Zhang L, Yang J and Sun R: LncRNA KCNQ1OT1 promotes cell proliferation, migration and invasion via regulating miR-129-5p/JAG1 axis in non-small cell lung cancer. Cancer Cell Int. 20:1442020. View Article : Google Scholar : PubMed/NCBI
135	Kang Y, Jia Y, Wang Q, Zhao Q, Song M, Ni R and Wang J: Long Noncoding RNA KCNQ1OT1 promotes the progression of non-small cell lung cancer via regulating miR-204-5p/ATG3 Axis. Onco Targets Ther. 12:10787–10797. 2019. View Article : Google Scholar : PubMed/NCBI
136	Dumanski JP, Halvardson J, Davies H, Rychlicka-Buniowska E, Mattisson J, Moghadam BT, Nagy N, Węglarczyk K, Bukowska-Strakova K, Danielsson M, et al: Immune cells lacking Y chromosome show dysregulation of autosomal gene expression. Cell Mol Life Sci. 78:4019–4033. 2021. View Article : Google Scholar : PubMed/NCBI
137	Lai IL, Chang YS, Chan WL, Lee YT, Yen JC, Yang CA, Hung SY and Chang JG: Male-specific long noncoding RNA TTTY15 inhibits non-small cell lung cancer proliferation and metastasis via TBX4. Int J Mol Sci. 20:34732019. View Article : Google Scholar : PubMed/NCBI
138	Yang CJ, Kumar A, Deng JZ, Raman V, Lui NS, D'Amico TA and Berry MF: A National analysis of short-term outcomes and long-term survival following thoracoscopic versus open lobectomy for clinical Stage II Non-Small-Cell lung cancer. Ann Surg. 273:595–605. 2021. View Article : Google Scholar
139	Zhang SB, Hong M, Sun XY, Huang D, He DH, Chen YF, Yuan Y and Liu YQ: Silybin has therapeutic efficacy against non-small cell lung cancer through targeting of Skp2. Acta Materia Medica. 1:302–313. 2022. View Article : Google Scholar
140	Jiang N, Meng X, Mi H, Chi Y, Li S, Jin Z, Tian H, He J, Shen W, Tian H, et al: Circulating lncRNA XLOC_009167 serves as a diagnostic biomarker to predict lung cancer. Clin Chim Acta. 486:26–33. 2018. View Article : Google Scholar : PubMed/NCBI
141	Zhu Z, Wang H, Pang Y, Hu H, Zhang H and Wang W: Exosomal long non-coding RNA UCA1 functions as growth inhibitor in esophageal cancer. Aging (Albany NY). 12:20523–20539. 2020. View Article : Google Scholar : PubMed/NCBI
142	Yu AM and Tu MJ: Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. Pharmacol Ther. 230:1079672022. View Article : Google Scholar :